Clinical Trial Detail

NCT ID NCT03134638
Title A Study of SY-1365 in Adult Patients With Advanced Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Syros Pharmaceuticals
Indications

Advanced Solid Tumor

fallopian tube cancer

peritoneal carcinoma

Her2-receptor negative breast cancer

ovarian clear cell carcinoma

ovarian serous carcinoma

Therapies

Carboplatin + SY-1365

SY-1365

Fulvestrant + SY-1365

Age Groups: adult senior

No variant requirements are available.